Your SlideShare is downloading. ×
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Innovative CA Tumor Marker Tests Technologies and Emerging Markets
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Innovative CA Tumor Marker Tests Technologies and Emerging Markets

157

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
157
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Innovative CA Tumor Marker Tests Technologies and EmergingMarketsReport Details:Published:November 2012No. of Pages: 278Price: Single User License – US$4850Presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US,Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and currentlaboratory practice; 5- and 10-year test volume and sales forecasts by country and marketsegment; as well as sales and market shares for major suppliers.The cancer diagnostics market ison the verge of explosion, as the researchers approach major technological breakthroughs intumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of thegenetic basis of the disease. During the next ten years, the worldwide cancer testing market ispromising to be an exciting, dynamic and rapidly expanding field. Anticipated technologicalbreakthroughs will create numerous opportunities for determining genetic predisposition, detectingspecific tumors, and monitoring biological response to cancer therapy. The rise in geriatricpopulation will further compound the growing demand for malignancy assays and the rapid marketexpansion worldwide.The report also examines market applications of DNA probes,biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and othertechnologies; reviews features and operating characteristics of automated analyzers; profilesleading suppliers and recent market entrants developing innovative technologies and products;and identifies alternative market penetration strategies and entry barriers/risks.Get your copy of this report @http://www.reportsnreports.com/reports/207480-innovative-ca-tumor-marker-tests-technologies-and-emerging-markets.htmlMajor points covered in Table of Contents of this report includeTable of ContentsI. IntroductionII. CA TUMOR MARKERS Worldwide Market and Technology OverviewA. CA Tumor Markers: Clinical Significanceand Laboratory Practices
  • 2. 1. CA 15-3/27.292. CA 19-93. CA 125B. Instrumentation Review AndMarket Needs1. Abbott AxSYM2. Abbott Architect c40003. Abbott Architect i2000 Series4. Abbott Architect ci8200 System5. Beckman Coulter UniCel Series6. Beckman Coulter Access7. Binding Site ESP6008. bioMerieux Mini Vidas9. Carolina Chemistries BioLis 24i10. DiaSorin Liaison11. Horiba ABX Pentra 40012. Inverness DS213. J&J Vitros ECi/ECiQ14. J&J Vitros 360015. J&J Vitros 560016. Olympus AU540017. Olympus AU3000i18. Olympus AU270019. Roche Modular Analytics20. Roche Cobas Integra 40021. Roche Cobas Integra 400 Plus22. Roche Elecsys23. Roche Cobas c31124. Siemens ADVIA Centaur25. Siemens Dimension26. Siemens Dimension RxL Max27. Siemens Dimension Vista 50028. Siemens Immulite29. Siemens Stratus30. Tosoh AIA-Series31. Vital Diagnostics ATAC 800032. Vital Diagnostics Envoy 500C. Current and Emerging Technologies1. Monoclonal and Polyclonal Antibodies2. Immunoassaysa. Technological Principleb. Radioimmunoassay (RIA)
  • 3. c. Enzyme Immunoassays (EIA)OverviewELISAImmunofiltrationParticle-Membrane Capture ImmunoassayEnzyme Amplificationd. Fluorescent Immunoassayse. LuminescenceChemiluminescenceBioluminescencef. Latex Agglutinationg. ImmunoprecipitationH. Affinity Chromatographue. Liposome Flow-Injection Immunoassay3. Molecular Diagnosticsa. Technology Overviewb. Amplification MethodsPCRDAP-PCRImmuno-PCRQC-PCRCARDNAHPALCRNASBAQBRSDA3 SR, and others4. Chromosome Analysisa. Chronic Myelogenous Leukemia (CML)b. Acute Myeloid Leukemia (AML)c. Acute Lymphoblastic Leukemia (ALL)d. Malignant LymphomasLymphoid Malignanciese. Chronic Lymphocytic Leukemia (CLL)f. Solid Cancersg. Chromosomal Translocation and Oncogenes5. Artificial Intelligence6. Flow Cytometry7. Two Dimensional Gel Electrophoresis (2-DGE)8. Biosensors
  • 4. 9. Competing/Complementing Technologiesa. CTb. MRIc. NMRd. PETe. Photonics SpectroscopyE. Personal TestingIII. France: Market Size, Growth and Major Suppliers’Sales and Market SharesIV. Germany: Market Size, Growth and Major Suppliers’Sales and Market SharesV. Italy: Test Volume and Diagnostics Sales Forecast by Market SegmentVI. Japan: Market Size, Growth and Major Suppliers’Sales and Market SharesVII. Spain: Market Size, Growth and Major Suppliers’Sales and Market SharesVIII. U.K.: Test Volume and Diagnostics Sales Forecast by Market SegmentIX. U.S.A.: Market Size, Growth and Major Suppliers’Sales and Market SharesX. Design Criteria for Decentralized Testing ProductsXI. Alternative Market Penetration StrategiesA. Internal DevelopmentB. Collaborative ArrangementsC. University ContractsD. Distribution Strategies1. Marketing Approaches2. Product Complexity3. Customer Preference4. Established Suppliers5. Emerging Suppliers6. Major Types of Distributors7. Market Segmentation Factor
  • 5. XII. Potential Market Entry Barriers and RisksA. Market MaturityB. Cost ContainmentC. CompetitionD. Technological Edge and LimitationsE. Patent ProtectionF. Regulatory ConstraintsG. Decentralized Testing Market ChallengesXIII. Competitive ProfilesAbbottAdnaGenApplied Gene TechnologiesArcaBeckman Coulter/DanaherBecton DickinsonBiomedical DiagnosticsbioMerieuxBio-RadCepheidCorrelogic SystemsDakoDecodeDiadexusDiagnocureDiasorinEiken ChemicalEnterixEnzo BiochemEpigenomicsExact SciencesFujirebioGen-ProbeGuided TherapeuticsHologicIpsogenKreatechKyowa MedexLife TechnologiesMackay Life SciencesMyriad GeneticsNanogen Elitech
  • 6. OncoLabOrtho-Clinical DiagnosticsPanacea PharmaceuticalsPolartechnicsPolymedcoPreMDQiagenRadient PharmaceuticalsRocheScienionSequenomSiemens HealthcareTakara BioTargeted Diagnostics & TherapeuticsTosohVeridexWako Pure ChemicalsWallac/PEZilaList of TablesMajor Companies Developing or Marketing CA 15-3/27.29 TestsMajor Companies Developing or Marketing CA 19-9 TestsMajor Companies Developing or Marketing CA 125 TestsFranceCA 15-3/27.29 Test Volume and Diagnostics Sales by Market SegmentFranceCA 19-9 Test Volume and Diagnostics Sales by Market SegmentFranceCA 125 Test Volume and Diagnostics Sales by Market SegmentFranceCA 15-3/27.29 Testing Market by Major Supplier FranceCA 19-9 Testing Market by Major SupplierFranceCA 125 Testing Market by Major SupplierGermanyCA 15-3/27.29 Test Volume and Diagnostics Sales by Market SegmentGermanyCA 19-9 Test Volume and Diagnostics Sales by Market SegmentGermanyCA 125 Test Volume and Diagnostics Sales by Market Segment
  • 7. GermanyCA 15-3/27.29 Testing Market by Major SupplierGermanyCA 19-9 Testing Market by Major SupplierGermanyCA 125 Testing Market by Major SupplierItalyCA 15-3/27.29 Test Volume and Diagnostics Sales by Market SegmentItalyCA 19-9 Test Volume and Diagnostics Sales by Market SegmentItalyCA 125 Test Volume and Diagnostics Sales by Market SegmentJapanCA 15-3/27.29 Test Volume and Diagnostics Sales by Market SegmentJapanCA 19-9 Test Volume and Diagnostics Sales by Market SegmentJapanCA 125 Test Volume and Diagnostics Sales by Market SegmentJapanCA 15-3/27.29 Testing Market by Major SupplierJapanCA 19-9 Testing Market by Major SupplierJapanCA 125 Testing Market by Major SupplierSpainCA 15-3/27.29 Test Volume and Diagnostics Sales by Market SegmentSpainCA 19-9 Test Volume and Diagnostics Sales by Market SegmentSpainCA 125 Test Volume and Diagnostics Sales by Market SegmentSpainCA 15-3/27.29 Testing Market by Major SupplierSpainCA 19-9 Testing Market by Major SupplierSpainCA 125 Testing Market by Major SupplierU.K.CA 15-3/27.29 Test Volume and Diagnostics Sales by Market SegmentU.K.CA 19-9 Test Volume and Diagnostics Sales by Market SegmentU.K.CA 125 Test Volume and Diagnostics Sales by Market Segment
  • 8. U.S.A.CA 15-3/27.29 Test Volume and Diagnostics Sales by Market SegmentU.S.A.CA 19-9 Test Volume and Diagnostics Sales by Market SegmentU.S.A.CA 125 Test Volume and Diagnostics Sales by Market SegmentU.S.A.CA 15-3/27.29 Testing Market by Major SupplierU.S.A.CA 19-9 Testing Market by Major SupplierU.S.A.CA 125 Testing Market by Major SupplierContact: sales@reportsandreports.com for more information.

×